en.Wedoany.com Reported - On June 12, Shanghai Kongshan Ci Technology Co., Ltd., which focuses on next-generation brain-computer interactive neuromodulation technology, completed its Series A funding round. This round was led by Oriental Fortune Capital, with participation from YaoTu Capital, and continued investment from existing shareholders DaoTong Investment and YunQi Capital. QiFeng Capital served as the financial advisor. The funds will be primarily used for product R&D iteration, medical device registration and application, and global expansion.
This investment targets the intersection of brain-computer interfaces and neuromodulation. Kongshan Ci's direction is not consumer-grade brain-computer concepts or single EEG acquisition devices, but rather a system platform for diagnosing and treating mental and cognitive disorders, encompassing brain function computation, positioning and navigation, and multimodal intervention. Treatments for mental illness, cognitive disorders, sleep disorders, and mood disorders have long faced challenges such as significant individual variability, complex efficacy evaluation, and difficult long-term management. Traditional treatment methods struggle to fully address the different brain functional states of patients. The value of brain-computer interactive neuromodulation lies in integrating brain function information acquisition, individualized target calculation, precise stimulation execution, and efficacy feedback loops into a single technical framework.
Kongshan Ci has currently established a system architecture comprising a "whole-brain functional connectivity computing engine + robot navigation + multimodal closed-loop regulation." Its underlying support includes brain functional connectivity computation, neuronavigation, medical imaging, acoustic engineering, artificial intelligence, and robotic execution capabilities, integrating different energy modalities such as magnetic, ultrasound, and electrical stimulation into a single intervention system. The challenge of this architecture is not merely combining multiple devices, but completing target calculation, energy path correction, real-time feedback, and safety control in clinical scenarios, transitioning neuromodulation from experience-based operations to more replicable and verifiable engineering processes.
This is also the reason for continued capital investment. On the product level, Kongshan Ci is advancing three main technology pipelines: transcranial focused ultrasound, navigated transcranial magnetic stimulation (TMS) system, and closed-loop electrical stimulation. Transcranial focused ultrasound can target deep brain regions, but energy attenuation and focal point shift after sound waves penetrate the skull are global challenges. Kongshan Ci is launching a self-developed 64 to 1024-channel transcranial focused ultrasound system, utilizing phase control and correction based on skull anatomical features to improve intervention precision in deep brain regions. The navigated TMS system is the company's first Class III medical device entering clinical registration, targeting indications like depression for precision treatment validation. The closed-loop electrical stimulation product relies on temporal interference electrical stimulation and EEG signal analysis modules, aiming to establish a continuous intervention pathway between intensive in-hospital treatment and long-term out-of-hospital management.
Clinical validation represents the most critical milestone for this company in its next phase. Data shows that Kongshan Ci's navigated TMS system has initiated multi-center clinical enrollment, with participation from four major national psychiatric medical centers: Beijing Anding Hospital, Shanghai Mental Health Center, the Second Xiangya Hospital of Central South University, and West China Hospital. For medical device companies, technological advancement is only the first step. Whether a product can truly transition from a research platform to a diagnostic and therapeutic tool depends on passing rigorous clinical evidence-based evaluation, generating stable efficacy data, completing registration applications, and entering hospital usage workflows. This Series A funding, explicitly directed towards medical device registration and application, indicates the company has entered a phase closer to industrial implementation.
Kongshan Ci's team structure also exhibits distinct interdisciplinary characteristics. Public information indicates that core team members cover neuroscience, acoustic engineering, medical imaging, artificial intelligence, robotics, and medical device registration. Brain-computer interactive neuromodulation is not a single software algorithm or a single hardware manufacturing process. It requires clinicians to pose real-world problems, engineering teams to solve energy delivery and device stability, algorithm teams to complete brain function modeling, and registration, quality system, and global compliance teams to bring the product to the medical market. The team's ability to cover these aspects directly impacts subsequent product iteration speed and clinical translation efficiency.
This funding round also sends a clearer industrial signal: brain-computer interfaces are moving from laboratory research and concept demonstrations into the stages of medical device development, clinical evidence generation, and global registration. Previously, brain-computer interfaces were often externally focused on human-computer interaction, rehabilitation control, and implantable devices. However, non-invasive neuromodulation has more direct clinical translation potential in the field of mental and cognitive disorders. It does not require large-scale craniotomy for implantation but can establish individualized treatment pathways centered on brain network targets, stimulation parameters, and feedback signals, suitable for hospital treatment, rehabilitation management, and some home-based device extensions.
The industrial chain impact will continue to spread from the R&D end to manufacturing, registration, and service ends. The upstream involves acoustic transducers, magnetic stimulation coils, electrical stimulation modules, EEG acquisition, medical imaging, sensors, robot navigation, and precision control components. The midstream involves neuromodulation devices, algorithm platforms, clinical data systems, quality systems, and medical device registration. The downstream connects psychiatric hospitals, neurology centers in general hospitals, rehabilitation institutions, out-of-hospital follow-up platforms, and international clinical collaboration networks. If Kongshan Ci's multiple pipelines can advance steadily, related demands will not be limited to single device procurement but will extend to diagnostic and therapeutic workflows, data platforms, physician training, and long-term management services.
Global expansion is another main line. Kongshan Ci plans to simultaneously pursue FDA and CE registration and promote the precision neuromodulation model validated in China to markets in North America, Europe, and Southeast Asia. This path is challenging; overseas registration requires supporting clinical data, quality systems, product safety, and indication design. However, if progress is smooth, Chinese brain-computer neuromodulation companies will no longer merely follow overseas technology routes but will have the opportunity to establish their own product definition rights in the fields of non-invasive brain-computer interfaces and precision intervention for mental illness.
Subsequent milestones focus on three aspects: First, the pace of product iteration following the injection of Series A funds, particularly whether the three pipelines of transcranial focused ultrasound, navigated TMS, and closed-loop electrical stimulation can form differentiated clinical positions. Second, the progress of clinical data for Class III medical device registration and whether multi-center validation can support subsequent applications. Third, the initiation status of overseas registration routes such as FDA and CE. If these aspects progress smoothly, Kongshan Ci will transition from a brain-computer interactive neuromodulation technology company into a platform-based medical device enterprise with registered products, clinical evidence, and global capabilities. For China's medical technology industry, the value of such financing lies not only in capital entering a frontier track but also in driving brain science, artificial intelligence, robotics, and medical device engineering towards genuine clinical application.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
